Assembly Biosciences (NASDAQ:ASMB – Get Free Report) and Heron Therapeutics (NASDAQ:HRTX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Assembly Biosciences and Heron Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Assembly Biosciences | 1 | 1 | 4 | 0 | 2.50 |
| Heron Therapeutics | 1 | 3 | 0 | 0 | 1.75 |
Assembly Biosciences currently has a consensus target price of $46.50, indicating a potential upside of 120.17%. Heron Therapeutics has a consensus target price of $2.00, indicating a potential upside of 544.12%. Given Heron Therapeutics’ higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Assembly Biosciences.
Valuation and Earnings
This table compares Assembly Biosciences and Heron Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Assembly Biosciences | $72.30 million | 5.95 | -$6.12 million | $1.02 | 20.71 |
| Heron Therapeutics | $154.90 million | 0.38 | -$20.19 million | ($0.12) | -2.59 |
Assembly Biosciences has higher earnings, but lower revenue than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 3.5% of Assembly Biosciences shares are owned by insiders. Comparatively, 6.1% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Assembly Biosciences and Heron Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Assembly Biosciences | -16.57% | -4.68% | -4.04% |
| Heron Therapeutics | -14.55% | -277.36% | -8.76% |
Risk & Volatility
Assembly Biosciences has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500.
Summary
Assembly Biosciences beats Heron Therapeutics on 8 of the 14 factors compared between the two stocks.
About Assembly Biosciences
Assembly Biosciences is a clinical-stage biotechnology company focused on developing oral antiviral therapies for viral infections. Its research programs target hepatitis B virus (HBV) and herpesviruses, including herpes simplex virus. The company’s pipeline includes investigational antiviral candidates designed to interfere with key steps in viral replication. Assembly has also worked with Gilead Sciences on antiviral development, including programs targeting herpesviruses. Its therapies remain under investigation and are not approved medicines.
About Heron Therapeutics
Heron Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for patients in acute care settings, including cancer treatment and surgery. Its work includes medicines intended to prevent nausea and vomiting associated with chemotherapy and surgery, as well as treatments for postsurgical pain. Heron’s products include CINVANTI and APONVIE, injectable formulations of aprepitant used to help prevent nausea and vomiting in specified clinical settings. The company also developed ZYNRELEF, a combination of bupivacaine and meloxicam for postsurgical pain, and SUSTOL, an extended-release formulation of granisetron for chemotherapy-related nausea and vomiting.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
